sanofi-aventis drops two Genfit compounds

sanofi-aventis (Euronext:SAN; NYSE:SNY) discontinued development of AVE8134 and AVE0847, which were developed with Genfit (Euronext:ALGFT) under a 1999 collaboration. AVE8134 is a peroxisome proliferation activated receptor (PPAR) alpha agonist, and AVE0847 is a PPAR alpha and gamma agonist. Both were in Phase IIa testing to treat mixed dyslipidemia and Type II diabetes. sanofi-aventis said it made the decision based on a "prioritization of its product portfolio." Genfit said it is examining the clinical results of the two compounds with the ultimate aim of pursuing clinical development of one or both of the compounds independently. ...